Journal
CLINICAL ONCOLOGY
Volume 33, Issue 1, Pages E73-E81Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.clon.2020.10.008
Keywords
Antibody; COVID-19; lateral flow device; oncology; SARS-CoV-2
Categories
Ask authors/readers for more resources
The COVID-19 pandemic has disrupted oncology services, and antibody testing is seen as a key activity for guiding treatment options and infection control measures. However, the reliability and immunity of antibody testing remain controversial.
The coronavirus disease 2019 (COVID-19) pandemic due to infection by a new human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), has seriously disrupted the provision of oncology services and their uptake. Antibody testing, both at an individual level and of populations, has been widely viewed to be a key activity for guiding the options for treatment of high-risk individuals, as well as the implementation of safe control of infection measures. Ideally, the detection of a specific antibody should signify that all individuals tested have been infected by SARS-CoV-2 and that in the case of specific IgG that they are immune to further infection. This would enable SARS-CoV-2-infected individuals to be appropriately managed and healthcare workers shown to be immune to return to work where they would no longer pose a risk to their patients or be at risk themselves. Unfortunately, this is not the case for COVID-19, where it has been shown that immunity may not be protective, and seroconversion delayed or absent. The variability in antibody test performance, particularly that of lateral flow assays, has caused confusion for the public and healthcare professions alike. Many antibody test devices have been made available without independent evaluations and these may lack both adequate sensitivity and specificity. This review seeks to educate healthcare workers, particularly those working in oncology, of the current benefits and limitations of SARS-CoV-2 antibody testing. (C) 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available